title: Potential options for managing LOX+ ER- breast cancer patients.
abstract: Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER-) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER- breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER- patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER- breast cancer patients, experiments to validate the function of LOX in ER- breast cancer are still needed.
authors.affiliation: Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Han
authors.affiliation: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, China.
authors.forename: Shenyi
authors.initials: S
authors.lastname: Lian
authors.affiliation: Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Xingran
authors.initials: X
authors.lastname: Cui
authors.affiliation: Department of Thyroid Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
authors.forename: Kexin
authors.initials: K
authors.lastname: Meng
authors.affiliation: Momentum Cancer Biomarker Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.|Second Department of Pediatrics, Semmelweis University, Budapest, Hungary.
authors.forename: Balázs
authors.initials: B
authors.lastname: Győrffy
authors.affiliation: Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Jin
authors.affiliation: Clinical Research Institute, Zhejiang Provincial People's Hospital, Hangzhou, China.
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000172:deficiency / Q000235:genetics*; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000401:mortality / Q000628:therapy*; D019295:Computational Biology; D030541:Databases, Genetic; D004164:Diphosphonates / Q000627:therapeutic use; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000172:deficiency / Q000235:genetics*; D005260:Female; D006801:Humans; D008249:Protein-Lysine 6-Oxidase / Q000235:genetics*; D011836:Radiation Tolerance; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004164:Diphosphonates; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D008249:Protein-Lysine 6-Oxidase
keywords: EMT; LOX; bisphosphonates; chemoresistance; estrogen recepter